As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit JV
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ranbaxy and Nihon Pharmaceuticals, a subsidiary of Japan's Nippon Chemiphar, look set to end a joint venture they signed in 2002 to make an early entry into the Japanese generic market. That move is triggered due to a potential conflict of interest between Nippon Chemiphar and Ranbaxy's majority stakeholder Daiichi Sankyo in approaching the Japanese generic market
You may also be interested in...
Nippon Chemiphar Parts Ways With Ranbaxy; Takes Over Generics Venture
Tokyo-based Nippon Chemiphar Dec. 8 announced a dissolution of its partnership with India's Ranbaxy Laboratories. A generic drug joint venture established by the two will become a Nippon Chemiphar wholly owned subsidiary
Nippon Chemiphar Parts Ways With Ranbaxy; Takes Over Generics Venture
Tokyo-based Nippon Chemiphar Dec. 8 announced a dissolution of its partnership with India's Ranbaxy Laboratories. A generic drug joint venture established by the two will become a Nippon Chemiphar wholly owned subsidiary
Nippon Chemiphar Parts Ways With Ranbaxy, Takes Over Generics Venture
The June takeover of Ranbaxy by Daiichi Sankyo sparked speculation over whether the joint venture would end.